Operative treatment of metastatic breast cancer in the spine with regard to molecular phenotypes

Abstract

With more than one million new diseases per year breast cancer is the most common malignancy in women. Metastatic breast cancer remains an incurable disease and the spinal column is most likely affected by metastases. A significantly prolonged patient survival is the consequence of modern oncologic treatment options in the last decade. Surgical treatment of vertebral metastases has become an increasing focus for spine surgeons. With the turn of the millennium it was possible to classify breast cancer into four intrinsic phenotypes with various survival rates. Well known scoring systems help surgeons to evaluate the patient´s prognosis and to choose adequate treatment options. However, tumor entities are differentiated without regard to the molecular subtypes. In this article we describe surgical treatment options in metastatic lesions to the spine with regard to molecular phenotypes of breast cancer malignancy. It is crucial to correctly estimate the expected survival time to plan invasiveness of therapy regarding metastatic spine surgery.

Keywords

Spine / metastases / breast cancer / phenotypes / subtypes / molecular level / prognosis

References

[1] AWMF online. Available from: https://www.awmf.org/uploads/tx_szleitlinien/032-045OLl_S3_Mammakarzinom_2018-09.pdf. [Last accessed on 25 Apr 2019]

[2] Bollen L,Wang M,Leithner A.Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases..Clin Exp Metastasis2015;32:1-5

[3] Wang M,Morgen SS,Sun M.Survival analysis of breast cancer subtypes in patients with spinal metastases..Spine (Phila Pa 1976)2014;39:1620-7

[4] Cardoso F,Senkus E,André F.3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)..Ann Oncol2017;28:3111 PMCID:PMC5834023

[5] Elkablawy MA,Mohammed RA.Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients..Saudi Med J2016;37:137-41 PMCID:PMC4800910

[6] Feeley LP,Pinnaduwage D.Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information..Mod Pathol2014;27:554-61

[7] Goldhirsch A,Coates AS,Thürlimann B.Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011..Ann Oncol2011;22:1736-47 PMCID:PMC3144634

[8] Harbeck N.Breast cancer: tumor biology-based concepts for surgical and drug treatment..Dtsch Med Wochenschr2013;138:180-2(in German)

[9] Jiehua Li,Ka Su.Clinicopathological classification and traditional prognostic indicators of breast cancer..Int J Clin Exp Pathol2015;8:8500-5 PMCID:PMC4555752

[10] Kobayashi K,Matsuura M,Horii R.Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer..Surg Today2016;46:821-6

[11] Putzier M.Diagnostic standards for extradural tumors and metastases of the spinal column..Orthopäde2013;42:691-9(in German)

[12] Sciubba DM,Suk I,Maldaun MV.Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease..Eur Spine J2007;16:1659-67 PMCID:PMC2078314

[13] Sciubba DM,Yurter A,Ziya LG.A systematic review of clinical outcomes and prognostic factors for patients undergoing surgery for spinal metastases secondary to breast cancer..Global Spine J2016;6:482-96 PMCID:PMC4947406

[14] Sorlie T,Tibshirani R,Johnson H.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications..Proc Natl Acad Sci U S A2001;98:10869-74 PMCID:PMC58566

[15] Tang P.Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 update..Arch Pathol Lab Med2016;140:806-14

[16] Bauer HC.Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients..Acta Orthop Scand1995;66:143-6

[17] Karnofsky DA.MacLeod CM.The clinical evaluation of chemotherapeutic agents in cancer..Evaluation of Chemotherapeutic Agents.1949;Columbia Univ Press191-205

[18] Tokuhashi Y,Oda H,Ryu J.A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis..Spine (Phila Pa 1976)2005;30:2186-91

[19] Tomita K,Kobayashi T,Murakami H.Surgical strategy for spinal metastases..Spine (Phila Pa 1976)2001;26:298-306

[20] Van der Linden YM,Vonk EJ,Leer JW.Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy..Cancer2005;103:320-8

[21] Von der Höh NH,Tschöke SK,Heyde CE.Prognosis scores for spinal metastases..Orthopäde2013;42:725-33

[22] Perou CM,Eisen MB,Jeffrey SS.Molecular portraits of human breast tumours..Nature2000;406:747-52

[23] Bastien RR,Ebbert MT,Munárriz B.PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers..BMC Med Genomics2012;5:44 PMCID:PMC3487945

[24] Blows FM,Schmidt MK,van Leeuwen FE.Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies..PLoS Med2010;7:e1000279 PMCID:PMC2876119

[25] Coleman R,Paterson A.Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials..Lancet2015;386:1353-61

[26] Godwin J,Clarke M,Darby S.Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials..Lancet2011;378:771-84 PMCID:PMC3163848

[27] Wolff AC,Hicks DG,McShane LM.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update..J Clin Oncol2013;31:3997-4013

[28] Harbeck N.Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer..J Clin Oncol2012;30:686-9

[29] Crockard A,Harms J,Mazel C.Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the global spine tumour study group..Eur Spine J2010;19:215-22 PMCID:PMC2899817

[30] Early Breast Cancer Trialists' Collaborative Group (EBCTCG)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials..Lancet2015;386:1341-52

[31] Holtkamp W,Wander HE,von Heyden D.Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer..Int J cancer1984;34:323-8

[32] Mullins M,Leung S,Vickery T.Supervised risk predictor of breast cancer based on intrinsic subtypes..J Clin Oncol2009;27:1160-7 PMCID:PMC2667820

[33] Sinn P,Wirtz R,Marmé F.Multigene assays for classification, prognosis, and prediction in breast cancer: a critical review on the background and clinical utility..Geburtshilfe Frauenheilkd2013;73:932-40 PMCID:PMC3859151

[34] Chia SK,D'yachkova Y,Malfair-Taylor S.The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer..Cancer2007;110:973-9

[35] Wang M,Li H,Høy K.Predictive value of Tokuhashi scoring systems in spinal metastases, focusing on various primary tumor groups: evaluation of 448 patients in the Aarhus spinal metastases database..Spine (Phila Pa 1976)2012;37:573-82

[36] Swain SM,Kim SB,Semiglazov V.Pertuzumab, Trastuzumab, and Docetaxel in HER2-positive metastatic breast cancer..N Engl J Med2015;372:724-34 PMCID:PMC5584549

[37] Peto R,Godwin J,Pan HC.Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials..Lancet2012;379:432-44 PMCID:PMC3273723

[38] Ulmer B,Cakir B.The Tokuhashi score: significant predictive value for the life expectancy of patients with breast cancer with spinal metastases..Spine (Phila Pa 1976)2005;30:2222-6

[39] Balain B,Trivedi JM,Kuiper JH.The Oswestry risk index: an aid in the treatment of metastatic disease of the spine..Bone Joint J2013;95-B:210-6

[40] Tokuhashi Y,Toriyama S,Ohsaka S.Scoring system for the preoperative evaluation of metastatic spine tumor prognosis..Spine (Phila Pa 1976)1990;15:1110-3

[41] Carlsson AM.Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale..Pain1983;16:87-101

[42] Fisher CG,Bilsky MH,Berven SH.A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the spine oncology study group..Spine (Phila Pa 1976)2010;35:E1221-9

[43] Harrington KD.Orthopedic surgical management of skeletal complications of malignancy..Cancer1997;80:1614-27

[44] Taneichi H,Takeda N,Satoh S.Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine..Spine (Phila Pa 1976)1997;22:239-45

[45] Majeed H,Bommireddy R,Calthorpe D.Accuracy of prognostic scores in decision making and predicting outcomes in metastatic spine disease..Ann R Coll Sure Engl2012;94:28-33 PMCID:PMC3954183

[46] Bullmann V.Operative treatment of spinal metastases..Orthopaädie und Unfallchirurgie up2date2010;5:279-94

[47] Heyde CE,von der Höh N,Jeszenszky D.Results-adapted operative treatment options for spinal metastases..Orthopäde2013;42:734-45

[48] Von Salis-Soglio G.Diagnostic methods in suspected malignant bone and soft tissue tumors..Orthopade2002;31:595-607

[49] Cho JH,Hwang CJ.Patterns of treatment for metastatic pathological fractures of the spine: the efficacy of each treatment modality..Clin Orthop Surgn2015;7:476-82 PMCID:PMC4667116

[50] Delank KS,Eich HT.The treatment of spinal metastases..Dtsch Arztebl Int2011;108:71-9 PMCID:PMC3036978

[51] Chen F,Cao WZ.Percutaneous kyphoplasty for the treatment of spinal metastases..Oncol Lett2016;11:1799-806 PMCID:PMC4774488

[52] Josten C, Glasmacher S, Franck A. Indikationen und grenzen der minimal-invasiven stabilisierung der metastatisch befallenen wirbelsäule. Orthopäde 2013;42:755-64. Available from: https://link.springer.com/article/10.1007%2Fs00132-013-2070-8. [Last accessed on 17 Apr 2019]

[53] Toquart A,Mansouri N.Management of spinal metastasis by minimal invasive surgery technique: surgical principles, indications: a literature review..Neurochirurgie2016;62:157-64

[54] Utzschneider S,Fottner,Jansson V.Prognosis-adapted surgical management of bone metastases..Orthopäde2009;38:308310-2, 314-5

[55] Chiras J,Jean B.Interventional radiology in bone metastases..Bull Cancer2007;94:161-9

[56] Nakatsuka A,Takaki H,Makita M.Percutaneous radiofrequency ablation of painful spinal tumors adjacent to the spinal cord with real-time monitoring of spinal canal temperature: a prospective study..Cardiovasc Intervent Radiol2009;32:70-5

[57] Zheng L,Sun M.A preliminary study of the safety and efficacy of radiofrequency ablation with percutaneous kyphoplasty for thoracolumbar vertebral metastatic tumor treatment..Med Sci Monit2014;20:556-63 PMCID:PMC3983101

[58] Delgado-López PD,Martín-Velasco V,Martín-Alonso J.Total en bloc spondylectomy for spinal tumours: technical aspects and surgical details..Neurocirugia2017;28:51-66

[59] Gezercan Y,Ökten AI.Single-stage posterolateral transpedicular approach with 360-degree stabilization and vertebrectomy in primary and metastatic tumors of the spine..World Neurosurg2016;95:214-21